Liminatus Pharma
LIMN
10 hedge funds and large institutions have $2.28M invested in Liminatus Pharma in 2025 Q2 according to their latest regulatory filings, with 10 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
0.79% more ownership
Funds ownership: 0% → 0.79% (+0.79%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$824K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$717K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$354K |
| 4 |
State Street
Boston,
Massachusetts
|
+$213K |
| 5 |
BlackRock
New York
|
+$149K |
Top Sellers
LIMN Hedge Fund Activity: Q2 2025 in Review
10 of the 7,616 institutional investors tracked by Wall St. Rank reported a position in Liminatus Pharma (LIMN) for Q2 2025, worth a combined $2.28M.
Buyers outnumbered sellers: 10 funds opened new LIMN positions and 0 closed out — a net gain of 10 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Vanguard Group, opening a new position worth an estimated $824K.
- 10 institutional investors held Liminatus Pharma (LIMN) as of Q2 2025, up from 0 in Q1 2025.
- Funds reported $2.28M of Liminatus Pharma stock for Q2 2025.
- 10 funds opened new Liminatus Pharma positions in Q2 2025 and 0 closed out, a net change of +10 holders.
- The largest Liminatus Pharma buyer in Q2 2025 was Vanguard Group, an estimated $824K added.
Based on aggregated 13F filings for Q2 2025.